Skip to content
aiqbench takeMachine Learning

aiqbench analysis

This study applies reverse Item Response Theory to reconstruct latent rankings in fragmented cancer drug-response data, demonstrating superior robustness against significant missingness compared to simple averaging methods. By modeling cancer types as subjects and drugs as items, the approach offers a methodological advance for handling sparse pharmacogenomic datasets rather than delivering immediate clinical tools.
Source coveringarXiv
What this isA model's reading of the article and related coverage, written for aiqbench. Not the publisher's words.

Reverse Item Response Theory for Sparsity-Robust Ranking in Fragmented Cancer Drug-Response Matrices

arXiv2 min read

arXiv:2610.00002v1 Announce Type: new Abstract: We introduce reverse Item Response Theory (IRT) to pharmacogenomic drug-response analysis by treating cancer types as latent "subjects" with resistance ability and drugs as "items" with evasion difficulty. Applied to 242,036 drug sensitivity measurements from the Genomics of Drug Sensitivity in Cancer (GDSC2) database, the model estimates cancer-type-level in-vitro resistance and drug-level broad activity on a shared latent scale. Validation across four missingness regimes demonstrates that reverse IRT better recovers the full-data latent ranking than simple averaging, with advantages of Delta-rho = +0.089 to +0.095 at 60% missingness under MCAR, cancer-biased, and drug-biased sparsity. Held-out prediction confirms IRT achieves the best Brier score among five evaluated methods. Bootstrap confidence intervals show 19 of 28 cancer types have stable resistant/sensitive classifications. Cross-platform PRISM replication shows 82% directional agreement but weak rank-order correlation (rho = 0.25), indicating the contribution is methodological robustness under fragmented evaluation, not a universal clinical resistance leaderboard.

Abstract:We introduce reverse Item Response Theory (IRT) to pharmacogenomic drug-response analysis by treating cancer types as latent "subjects" with resistance ability and drugs as "items" with evasion difficulty. Applied to 242,036 drug sensitivity measurements from the Genomics of Drug Sensitivity in Cancer (GDSC2) database, the model estimates cancer-type-level in-vitro resistance and drug-level broad activity on a shared latent scale. Validation across four missingness regimes demonstrates that reverse IRT better recovers the full-data latent ranking than simple averaging, with advantages of Delta-rho = +0.089 to +0.095 at 60% missingness under MCAR, cancer-biased, and drug-biased sparsity. Held-out prediction confirms IRT achieves the best Brier score among five evaluated methods. Bootstrap confidence intervals show 19 of 28 cancer types have stable resistant/sensitive classifications. Cross-platform PRISM replication shows 82% directional agreement but weak rank-order correlation (rho = 0.25), indicating the contribution is methodological robustness under fragmented evaluation, not a universal clinical resistance leaderboard.

Machine Learning (cs.LG)

arXiv:2610.00002 [cs.LG]

(or arXiv:2610.00002v1 [cs.LG] for this version)

https://doi.org/10.48550/arXiv.2610.00002 Focus to learn more arXiv-issued DOI via DataCite

arXivLabs is a framework that allows collaborators to develop and share new arXiv features directly on our website.

Both individuals and organizations that work with arXivLabs have embraced and accepted our values of openness, community, excellence, and user data privacy. arXiv is committed to these values and only works with partners that adhere to them.

Have an idea for a project that will add value for arXiv's community? Learn more about arXivLabs.

Full text under the publisher's open licence · 241 words

Related coverage